Examkin

Question

Difficulty: Very hardHealth Promotion and Disease Prevention

A registered nurse in an outpatient rheumatology setting is coordinating preventive health measures for a 28-year-old client with newly diagnosed systemic lupus erythematosus (SLE). The healthcare provider plans to initiate severe immunosuppressive therapy with high-dose corticosteroids and methotrexate in exactly four weeks. The client's immunization records indicate no vaccines have been administered since 11 years of age. To ensure safe and effective disease prevention, which of the following immunizations must the nurse prioritize administering at today's visit?

  1. Measles, mumps, and rubella (MMR) vaccineAnswer
  2. B
    Tetanus, diphtheria, and acellular pertussis (Tdap) vaccine
  3. C
    Pneumococcal conjugate vaccine
  4. D
    Inactivated influenza vaccine

Answer

The correct priority is the measles, mumps, and rubella (MMR) vaccine.
The measles, mumps, and rubella (MMR) vaccine is a live-attenuated virus vaccine. Health promotion and disease prevention guidelines mandate that live vaccines are absolutely contraindicated in clients actively receiving severe immunosuppressive therapy (such as high-dose corticosteroids and methotrexate) due to the risk of vaccine-induced disseminated infection. To ensure safety and efficacy, any required live vaccines must be administered at least 4 weeks prior to the initiation of immunosuppressive medications. The other options are inactivated vaccines, which can safely be administered during active immunosuppressive therapy.

Step-by-Step Solution

1
Analyze the client's upcoming medical treatment and timeline.
The client will begin severe immunosuppressive therapy in exactly four weeks.
Immunosuppression severely alters the safety profile and efficacy of various health promotion interventions, specifically immunizations.
2
Classify the immunization options by formulation.
The MMR vaccine is live-attenuated. Tdap, pneumococcal conjugate, and injectable influenza vaccines are inactivated.
Vaccine formulation determines whether it can be safely administered to a client with a compromised immune system.
3
Apply evidence-based disease prevention guidelines for live vaccines.
Live-attenuated vaccines carry a high risk of causing systemic infection in immunocompromised hosts and must be given a minimum of 4 weeks before immunosuppressive therapy begins.
This 4-week window allows the immune system to process the live vaccine and clear the attenuated viral replication before host defenses are suppressed.
4
Determine the highest priority intervention for today's visit.
The MMR vaccine must be administered today, as the window of opportunity to safely provide this primary prevention measure will permanently close once therapy begins.
Inactivated vaccines are safe to administer during active immunosuppressive therapy and can be deferred to a later visit if necessary.

Key Concept

In health promotion and disease prevention, live-attenuated vaccines are contraindicated during severe immunosuppression and must be administered at least 4 weeks prior to the initiation of immunosuppressive therapy.
Rate this question

Topics

Health Promotion and Disease Prevention

More questions from this topic